N. Renée

发表

Effect of dose and repeat intravenous 24 hr infusions of methotrexate on cerebrospinal fluid availability in children with hematological malignancies.

G. Milano, A. Thyss, A. Deville, 1987, European journal of cancer & clinical oncology.

G Milano, M. Barberi-Heyob, G. Milano, 2022 .

Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses.

N. Magné, P. Laurent-Puig, C. Létoublon, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An analysis of potential factors allowing an individual prediction of cisplatin-induced anaemia.

N. Magné, X. Pivot, G. Milano, 2000, European journal of cancer.

A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage.

X. Pivot, G. Milano, P. Canal, 2000, European journal of cancer.

Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours.

M. Namer, J. Formento, G. Milano, 1987, British Journal of Cancer.

Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolites.

G. Milano, M. Etienne-Grimaldi, E. François, 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Phase I Trial of Gemcitabine Combined with Capecitabine and Erlotinib in Advanced Pancreatic Cancer: A Clinical and Pharmacological Study

J. Douillard, G. Milano, P. Follana, 2012, Chemotherapy.

Erlotinib in Combination with Capecitabine (5'dFUR) in Resistant Pancreatic Cancer Cell Lines

G. Milano, J. Fischel, J. Ciccolini, 2010, Journal of chemotherapy.

A Clinical Pharmacokinetic Analysis of Tegafur-Uracil (UFT) Plus Leucovorin Given in a New Twice-Daily Oral Administration Schedule

J. Douillard, G. Milano, J. Cardot, 2007, Clinical pharmacokinetics.

[Population study of dihydropyrimidine dehydrogenase in cancer patients].

O. Dassonville, F. Demard, G. Milano, 1994, Bulletin du cancer.

Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase

G. Milano, J. Fischel, P. Formento, 1996, Cancer Chemotherapy and Pharmacology.

Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity.

O. Dassonville, F. Demard, G. Milano, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil.

G. Milano, J. Fischel, P. Formento, 1994, European journal of cancer.

K-Ras Mutations and Treatment Outcome in Colorectal Cancer Patients Receiving Exclusive Fluoropyrimidine Therapy

P. Laurent-Puig, C. Létoublon, G. Milano, 2008, Clinical Cancer Research.

Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients.

F. Demard, G. Milano, R. Fleming, 1992, Cancer research.

Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants

G. Milano, A. Iliadis, J. Fischel, 2012, Fundamental & clinical pharmacology.

Pharmacogenetics of Capecitabine in Advanced Breast Cancer Patients

M. Namer, G. Milano, R. Largillier, 2006, Clinical Cancer Research.

Response of epidermal polyamines to orally administered aromatic retinoid RO 10-9359

J. Ortonne, G. Milano, P. Verrando, 2004, Archives of Dermatological Research.

Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer

F. Demard, G. Milano, J. Vallicioni, 2004, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics of sunitinib in hemodialysis.

G. Milano, M. Etienne-Grimaldi, H. Izzedine, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Dihydropyrimidine dehydrogenase circadian rhythm in mouse liver: comparison between enzyme activity and gene expression.

N. Magné, F. Lévi, G. Milano, 2003, European journal of cancer.

Influence of sex and age on fluorouracil clearance.

F. Demard, J. Santini, G. Milano, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer.

F. Demard, J. Santini, G. Milano, 1989, British Journal of Cancer.

Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver.

G. Milano, M. Chazal, A. Bourgeon, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion.

F. Demard, G. Milano, R. Fleming, 1992, British Journal of Cancer.

Relationship between fluorouracil systemic exposure and tumor response and patient survival.

A. Ramaioli, F. Demard, G. Milano, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tipifarnib Plus Tamoxifen in Tamoxifen-Resistant Metastatic Breast Cancer: A Negative Phase II and Screening of Potential Therapeutic Markers by Proteomic Analysis

B. Monsarrat, G. Favre, F. Dalenc, 2010, Clinical Cancer Research.

Dose Versus pharmacokinetics for predicting tolerance to 5‐day continuous infusion of 5‐FU

M. Namer, G. Milano, M. Frénay, 1988, International journal of cancer.

ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine.

N. Magné, A. Dubreuil, G. Milano, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Impact of platinum complexes on dihydropyrimidine dehydrogenase activity in 5-fluorouracil-treated patients.

N. Magné, F. Demard, X. Pivot, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Population study of dihydropyrimidine dehydrogenase in cancer patients.

F Demard, G Milano, O. Dassonville, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dihydropyrimidine dehydrogenase activity in cancer patients.

F. Demard, G. Milano, R. Fleming, 1993, European journal of cancer.

Doxorubicin weekly low dose administration: in vitro cytotoxicity generated by the typical pharmacokinetic profile.

M. Namer, G. Milano, J. Fischel, 1992, European journal of cancer.

Pharmacokinetics of weekly low dose doxorubicin.

M. Namer, G. Milano, A. Thyss, 1989, European journal of cancer & clinical oncology.

Wound healing is not impaired by the epidermal growth factor receptor-tyrosine kinase inhibitor gefitinib

N. Magné, F. Demard, X. Pivot, 2003 .

Continuous 5-day regional chemotherapy by 5-fluorouracil in colon carcinoma: pharmacokinetic evaluation.

M. Namer, G. Milano, A. Thyss, 1985, British Journal of Cancer.

Pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate in advanced breast cancer patients.

M. Namer, G. Milano, A. Thyss, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HPLC micromethod for simultaneous measurement of estradiol, progesterone, androgen and glucocorticoid receptor levels. Application to breast cancer biopsies.

M. Namer, B. Krebs, G. Milano, 1987, European journal of cancer & clinical oncology.

Molecular mechanisms underlying the interaction between ZD1839 (‘Iressa’) and cisplatin/5-fluorouracil

N. Magné, A. Dubreuil, J. Formento, 2003, British Journal of Cancer.

High-performance liquid chromatographic assay with ultraviolet detection for quantification of dihydrofluorouracil in human lymphocytes: application to measurement of dihydropyrimidine dehydrogenase activity.

G. Milano, L. Campion, M. Amiand, 2001, Journal of chromatography. B, Biomedical sciences and applications.

Cisplatin Nephrotoxicity: A Multivariate Analysis of Potential Predisposing Factors

X. Pivot, G. Milano, J. Ferrero, 1997, Pharmacotherapy.

[Dihydropyrimidine dehydrogenase activity in lymphocytes: predictive factor for 5-fluorouracil clearance].

F. Demard, G. Milano, R. Fleming, 1992, Bulletin du cancer.

Single Ascending Dose Tolerability, Pharmacokinetic–Pharmacodynamic Study of Dihydropyrimidine Dehydrogenase Inhibitor Ro 09-4889

G. Milano, S. Nave, E. Chamorey, 2004, Clinical Cancer Research.

Chronopharmacokinetics of Oral Tegafur and Uracil in Colorectal Cancer Patients

J. Douillard, G. Milano, J. Cardot, 2008, Clinical pharmacology and therapeutics.

A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma.

G. Milano, M. Etienne-Grimaldi, H. Izzedine, 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Pharmacokinetics of low-dose carboplatin and applicability of a method of calculation for estimating individual drug clearance.

N. Magné, X. Pivot, G. Milano, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.